New registry tracks rezdiffra safety for moms and babies

NCT ID NCT07541469

Recruiting now Knowledge-focused Sponsor: Madrigal Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen May 01, 2026 · Last updated Jun 06, 2026 · Updated 10 times

Summary

This study tracks the safety of the liver drug Rezdiffra (resmetirom) in women with NASH who take it while pregnant or breastfeeding. Researchers will follow about 10 women and their infants up to 12 months old to check for birth defects, growth problems, and other health issues. No new treatment is given—it simply collects real-world information to better understand risks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Madrigal Pharmaceuticals
RECRUITING

West Conshohocken, Pennsylvania, 19428, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS